Clinical Trial Update: Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of Brentuximab Vedotin and Bendamustine for relapsed or refractory follicular lymphoma and is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• Treanda (Bendamustine)

Snippet

Sponsor: Joseph Tuscano | Conditions: Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Status: RECRUITING